Evidence map›Paper›PMID 35814239›Full record

ArticleFrontiers in pharmacology2022

The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis.

Lanmei Lin, Yilun Wang, Xiaonian Lu, Tianxiao Wang, Qunyi Li, Runnan Wang, Jinfeng Wu, Jinhua Xu, Juan Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lanmei LinDepartment of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
Yilun WangDepartment of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
Xiaonian LuDepartment of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
Tianxiao WangDepartment of Pharmacy, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
Qunyi LiDepartment of Pharmacy, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
Runnan WangDepartment of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
Jinfeng WuDepartment of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
Jinhua XuDepartment of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
Juan DuDepartment of Dermatology, Huashan Hospital Affiliated to Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is a common immune-mediated inflammatory skin disease. Although biological agents have achieved good clinical efficacy in the treatment of moderate-to-severe psoriasis, the phenomenon of secondary non-response (SNR) has been gradually recognized. SNR refers to the gradual decline of efficacy after the patient achieves clinical remission with biological agents such as TNF-α biologics. Acitretin, as an immunomodulatory systemic drug for psoriasis, can improve the SNR to biological agents with good tolerance, but there are still individual differences in efficacy. Single-nucleotide polymorphisms (SNPs) of many related inflammatory cytokines have been shown to be important factors of individual differences in drug response in psoriasis, but there have been few reports on the use of pharmacogenomics to alleviate the SNR to biological agents. This study recruited 43 patients with psoriasis and 24 normal controls to investigate whether SNPs of inflammatory cytokines could be used as biomarkers for acitretin to alleviate SNR to TNF-α biologics in psoriasis, including rs1800795 (IL-6), rs6887695 (IL-12b), rs3212227 (IL-12b), rs10484879 (IL-17a), rs4819554 (IL-17ra), rs763780 (IL-17F), rs11209032 (IL23R), rs11209026 (IL23R), and rs2201841 (IL23R). The study also analyzed the correlation between the abovementioned SNPs and the efficacy of acitretin-only patients so as to understand whether the improvement is attributable to the intervention of acitretin on SNR or a simple response of acitretin. We found that in patients with homozygous AA (χ2 = 6.577,

Indexed as

acitretinbiologicspsoriasissecondary non-responsesingle-nucleotide polymorphism (SNP)

Identifiers

PMID35814239
PMCPMC9263382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.